4569

KYORIN Pharmaceutical Co., Ltd.

杏林製薬株式会社
Pharmaceutical
KYORIN Pharmaceutical Co., Ltd., through its subsidiaries, researches and develops, manufactures, and sells ethical and generic drugs in Japan and internationally. The company offers Flutiform, a drug for the treatment of asthma; Lyfuna for cough treatment; Desalex, an antiallergic agent; Beova, and Uritos KYORIN therapeutic agents for overactive bladder; Lasvic, a quinolone synthetic antibacterial agent; Pentasa, a remedy for ulcerative colitis/Crohn's disease; Nasonex and Mometasone KYORIN, which are used as allergic rhinitis therapeutic agents; and Kipres, a leukotriene receptor antagonist anti-bronchial asthma and allergic rhinitis drug. It also provides Mucodyne, a mucoregulating drug; GeneSoC, a real-time PCR system; Rubysta, a disinfectant cleaner; Milton, a disinfectant; over-the-counter drugs; and prescription medicines and quasi-drugs, and diagnostics business. In addition, the company offers subcontracted drug manufacturing services. It has development and commercialization agreement with Hyfe Inc. for digital therapeutics (DTx) for chronic cough. The company was formerly known as KYORIN Holdings, Inc. KYORIN Pharmaceutical Co., Ltd. was founded in 1923 and is headquartered in Tokyo, Japan.
← Companies
Price
¥1,266
Market Cap
¥73.6B
Ent. Value
¥85.1B
Net Debt
−¥11.5B
Shares Out.
58.1M
P / E
21.1×
EV / EBIT
23.9×
⚠ TSE Capital Mandate
P / Book
0.51×
P / NCAV
0.90×
Div. Yield
1.58%
Financials
Metric FY 2025
TDnet 		FY 2024
EDINET ↗ 		FY 2023
EDINET ↗ 		FY 2022
EDINET ↗ 		FY 2021
EDINET ↗
Net Sales ¥126.3B ¥130.1B ¥119.5B ¥113.3B ¥105.5B
Cost of Sales ¥74.6B ¥70.6B ¥68.1B ¥63.1B ¥56.1B
Gross Profit ¥51.6B ¥59.5B ¥51.4B ¥50.2B ¥49.4B
SG&A ¥48.1B ¥47.0B ¥45.4B ¥45.0B ¥44.4B
Operating Income ¥3.6B ¥12.6B ¥6.0B ¥5.1B ¥5.0B
Non-Operating Income ¥812M ¥870M ¥735M ¥799M ¥677M
Dividend Income — ¥496M ¥459M ¥446M ¥408M
Interest Income — ¥1M ¥41M ¥19M ¥2M
Non-Operating Expenses — ¥218M ¥146M ¥94M ¥115M
Interest Expense — ¥173M ¥66M ¥66M ¥66M
Ordinary Income ¥4.0B ¥13.2B ¥6.6B ¥5.8B ¥5.6B
Pre-tax Income ¥4.5B ¥12.8B ¥7.0B ¥6.9B ¥5.2B
Income Taxes ¥1.0B ¥3.7B ¥1.7B ¥2.2B ¥1.3B
Current Tax — ¥3.8B ¥1.9B ¥2.5B ¥1.6B
Deferred Tax — ¥-123M ¥-200M ¥-279M ¥-346M
Net Income (owners) ¥3.4B ¥9.1B ¥5.3B ¥4.7B ¥3.9B
Comprehensive Income — ¥8.6B ¥7.9B ¥4.0B ¥3.6B
EBITDA ¥8.2B ¥17.2B ¥10.3B ¥9.0B ¥8.7B
EPS ¥60.03 ¥158.17 ¥92.74 ¥82.44 ¥68.62
Shares Outstanding — 58.1M 58.1M 58.1M 58.1M
Shares Issued (total) — 64.6M 64.6M 64.6M 64.6M
Treasury Shares — 6.5M 6.5M 6.5M 6.5M